Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Sales35,559,985,569,213263,1
EBITDA-68,4-66,9-54,4-114-36,6-84,4
Operating profit (EBIT)-73,0-71,5-59,9-113-44,9-121
Pre-Tax Profit (EBT)-72,8-----
Net income-72,8-71,4-60,7-131-64,8-144
P/E ratio-19,1-14,3-20,3-4,22-8,75-4,22
EPS ( $ )-0,87-0,83-0,71-1,52-0,73-1,52
Dividend per Share ( $ )------
Yield------
Reference price ( $ )16.5911.8514.386.426.426.42
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period June 201320142015201620172018
Debt---19,2164138
Finance195142278---
Operating income (EBITDA)-68,4-66,9-54,4-114-36,6-84,4
Leverage
(Debt/EBITDA)
----0,17x-4,48x-1,64x
Capital Expenditure3,778,187,4314,05,436,30
Book Value Per Share (BVPS)1,44 $0,88 $0,41 $-0,85 $-0,80 $-1,81 $
Cash Flow per Share-0,72 $-0,63 $-0,64 $-1,32 $-0,71 $-1,00 $
Announcement Date08/02/2013
10:30am
08/01/2014
10:30am
07/31/2015
10:30am
---
Balance Sheet Analysis
Assessed data source :
© 2017 Thomson Reuters
Financial Ratios

Size 2016e 2017e
Capitalization 720 M$ -
Entreprise Value (EV) 740 M$ 884 M$
Valuation 2016e 2017e
P/E ratio (Price / EPS)
Capitalization / Revenue 10,4x 5,47x
EV / Revenue 10,7x 6,71x
EV / EBITDA -6,48x -24,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) -7,55x -8,03x
Profitability 2016e 2017e
Operating Margin (EBIT / Sales) -163% -34,1%
operating Leverage (Delta EBIT / Delta Sales) -4,63x 0,67x
Net Margin (Net Profit / Revenue) -190% -49,2%
ROA (Net Profit / Asset) -53,0% -28,6%
ROE (Net Profit / Equities) 2 183% -
Rate of Dividend - -
Balance Sheet Analysis 2016e 2017e
CAPEX / CA   20,2% 4,12%
Cash Flow / Sales -214% -60,5%
Capital Intensity (Assets / Sales) 3,58x 1,72x
Financial Leverage (Net Debt / EBITDA) -0,17x -4,48x
EPS & Dividend